Results 11 to 20 of about 324,354 (294)

Immunotherapy of cancer [PDF]

European Journal of Pharmacology, 2009
Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response.
Kerry S. Campbell, Hossein Borghaei, Mitchell R. Smith   +2 more
openaire   +3 more sources

The Evolution of Cancer Immunotherapy [PDF]

Vaccines, 2021
Immunotherapy has changed the environment of cancer treatment by providing new and efficacious therapy options for many solid and hematologic malignancies. Although not a new field of oncology, immunotherapy has quickly developed into one of the most flourishing fields in medicine.
Meshaal Khan, Ajay V. Maker, Shikha Jain
openaire   +6 more sources

Biomarkers in Cancer Immunotherapy [PDF]

Cancer Cell, 2015
Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer ...
Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M   +2 more
openaire   +4 more sources

ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism

OncoImmunology, 2017
Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach, Jan Winter, Miriam Reuschenbach, Renata Blatnik, Alexandra Klevenz, Miriam Bertrand, Stephanie Hoppe, Magnus von Knebel Doeberitz, Agnieszka K. Grabowska, Angelika B. Riemer   +9 more
doaj   +1 more source

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Frontiers in Pharmacology, 2023
Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated ...
Yosuke Shibata, Takeshi Kishida, Taku Kouro, Taku Kouro, Feifei Wei, Feifei Wei, Yuka Igarashi, Yuka Igarashi, Hidetomo Himuro, Hidetomo Himuro, Takeaki Noguchi, Mitsuyuki Koizumi, Takahisa Suzuki, Kimito Osaka, Yusuke Saigusa, Tetsuro Sasada, Tetsuro Sasada   +16 more
doaj   +1 more source

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model

OncoImmunology, 2019
Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages.
Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier, Angelika B. Riemer   +11 more
doaj   +1 more source

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Journal for ImmunoTherapy of Cancer, 2019
Background High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to engineer potent T cells for therapeutic treatment of cancer patients.
Junko Matsuzaki, Takemasa Tsuji, Thinle Chodon, Courtney Ryan, Richard C. Koya, Kunle Odunsi   +5 more
doaj   +1 more source

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

Cancer Medicine, 2020
Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy.
Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad   +19 more
doaj   +1 more source

Cancer Immunotherapy

Molecular Oncology, 1999
The remarkable specificity of the immune system through antigen recognition has long attracted investigators to the possibility of immune‐based therapy for cancer. Previous cancer immunotherapeutics had been restricted to non‐specific immunomodulatory agents, such as the cytokines IL‐2 or IFN‐α.
openaire   +3 more sources

Immunotherapy in Gastrointestinal Cancers [PDF]

BioMed Research International, 2017
Gastrointestinal cancers represent a major public health problem worldwide. Immunotherapeutic strategies are currently under investigation in this setting and preliminary results of ongoing trials adopting checkpoint inhibitors are striking. Indeed, although a poor immunogenicity for GI has been reported, a strong biological rationale supports the ...
Procaccio, Letizia, Schirripa, Marta, Fassan, Matteo, Vecchione, Loredana, Bergamo, Francesca, Prete, Alessandra Anna, Intini, Rossana, Manai, Chiara, Dadduzio, Vincenzo, Boscolo, Alice, Zagonel, Vittorina, Lonardi, Sara   +11 more
openaire   +3 more sources